Comparative Pharmacology
Head-to-head clinical analysis: FLOXIN IN DEXTROSE 5 versus PROQUIN XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOXIN IN DEXTROSE 5 versus PROQUIN XR.
FLOXIN IN DEXTROSE 5% vs PROQUIN XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
Fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.
400 mg intravenously every 12 hours.
500 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (prolonged in renal impairment, up to 20-30 hours in severe impairment).
Terminal elimination half-life is approximately 10-14 hours in patients with normal renal function (CrCl >80 mL/min). Extended half-life may occur in renal impairment, necessitating dose adjustment.
Primarily renal (approximately 70-90% unchanged drug), with 5-10% biliary/fecal elimination.
Primarily renal excretion of unchanged drug (~60-80%) via glomerular filtration and tubular secretion. Biliary/fecal excretion accounts for approximately 20-35%, with a small portion as metabolites.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic